Lexaria Bioscience Corp. Total Revenue

• Lexaria Bioscience Corp. showed an increase of +52.0% in Total Revenue from 2024 to 2025.
• This data is from Lexaria Bioscience Corp.'s annual report (Form 10-K), filed with the SEC on November 28, 2025.
• XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: $15.2 thousand | Q2 2016: $6.2 thousand | Q4 2016: $9.2 thousand | Q1 2017: $12.6 thousand | Q2 2017: $29.3 thousand | Q4 2017: $24.6 thousand | Q4 2017: $24.6 thousand | Q1 2018: $172.0 thousand | Q1 2018: $172.0 thousand | Q2 2018: $140.3 thousand | Q2 2018: $140.3 thousand | Q4 2018: $22.2 thousand | Q1 2019: $15.3 thousand | Q2 2019: $59.9 thousand | Q4 2019: $10.3 thousand | Q1 2020: $37.5 thousand | Q2 2020: $36.4 thousand | Q4 2020: $295.7 thousand | Q4 2020: $295.7 thousand | Q1 2021: $192.0 thousand | Q1 2021: $192.0 thousand | Q2 2021: $204.1 thousand | Q2 2021: $204.1 thousand | Q4 2021: $13.9 thousand | Q1 2022: $30.7 thousand | Q2 2022: $99.7 thousand | Q4 2022: $97.7 thousand | Q1 2023: $20.0 thousand | Q2 2023: $77.7 thousand | Q4 2023: $151.3 thousand | Q1 2024: $145.0 thousand | Q2 2024: $84.0 thousand | Q4 2024: $183.9 thousand | Q1 2025: $174.0 thousand | Q2 2025: $174.0 thousand | Q4 2025: $0.00.
• Over the full 9 years of available data (2018 to 2025), Lexaria Bioscience Corp.'s Total Revenue has grown by 62.9%.
• Historical annual values: Fiscal year 2025: $705.9 thousand | Fiscal year 2024: $464.3 thousand | Fiscal year 2023: $226.2 thousand | Fiscal year 2022: $255.4 thousand | Fiscal year 2021: $722.7 thousand | Fiscal year 2020: $314.8 thousand | Fiscal year 2020: $384.5 thousand | Fiscal year 2019: $222.6 thousand | Fiscal year 2018: $433.3 thousand.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026